Ajanta Pharma (AJANTPHARM.NS) Stock Price
Ajanta Pharma Price
Revenue has compounded at 17.4% per year over the past 19 years to 54.53 B INR. Earnings per share have grown at 25.2% per year over the last 19 years. Ajanta Pharma's net margin stands at 19.4%, down from 21.7% several years earlier. Ajanta Pharma currently offers a dividend yield of about 0.85%. The payout ratio is around 58% of earnings. The dividend has grown at 30.5% per year over the past 19 years. Analysts set a median price target of 3,304.80 INR, implying 0.6% above the current price. Of 20 analysts, 18 rate the stock a buy — an overall Buy consensus.
Ajanta Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Ajanta Pharma business model & stock analysis
Frequently asked questions about Ajanta Pharma
The business model of Ajanta Pharma Ltd is centered around the manufacturing and marketing of generic pharmaceutical products. Ajanta Pharma specializes in the development, manufacture, and marketing of generic medicines across various therapeutic segments, including cardiovascular, dermatology, ophthalmology, and more. The company focuses on providing affordable and high-quality pharmaceutical products to customers globally. Ajanta Pharma's diverse product portfolio caters to the needs of diverse markets through its strong distribution network. With its commitment to innovation, quality, and customer satisfaction, Ajanta Pharma continues to establish itself as a leading player in the global pharmaceutical industry.
Ajanta Pharma Ltd is primarily active in the pharmaceutical industry.
The main competitors of Ajanta Pharma Ltd in the market include Sun Pharmaceutical Industries Ltd, Cipla Ltd, Lupin Ltd, and Dr. Reddy's Laboratories Ltd.
Ajanta Pharma Ltd is a leading pharmaceutical company headquartered in India. It was established in 1973 and has since witnessed substantial growth in the global healthcare industry. Ajanta Pharma specializes in the development, manufacturing, and marketing of high-quality generic and branded drugs. With a strong focus on research and development, the company has created a diverse product portfolio across numerous therapeutic areas. Ajanta Pharma's commitment to quality and affordability has enabled it to penetrate various international markets and gain a reputation as a reliable pharmaceutical provider. With a consistent track record of success, Ajanta Pharma continues to play a notable role in improving global healthcare access.
Ajanta Pharma Ltd has achieved several significant milestones. The company has successfully established a global presence by exporting its pharmaceutical products to over 50 countries. Ajanta Pharma Ltd has received various certifications and accreditations, including US FDA approval, WHO GMP certification, and ISO 9001:2015 certification for its manufacturing facilities. The company has also been recognized for its research and development capabilities, launching multiple innovative and affordable generic pharmaceutical products. With its strong commitment to quality and customer satisfaction, Ajanta Pharma Ltd has become a trusted name in the pharmaceutical industry globally.
Ajanta Pharma Ltd is primarily present in various countries and regions across the globe. The company has a significant presence in India, where it is headquartered. Additionally, Ajanta Pharma Ltd has established a strong foothold in the United States, Europe, Asia, Africa, and Latin America. With its expanding market presence, Ajanta Pharma Ltd continues to cater to the healthcare needs of patients worldwide, delivering quality pharmaceutical products and contributing to global healthcare.
Ajanta Pharma Ltd represents values of innovation, excellence, and integrity in the pharmaceutical industry. The company is committed to delivering high-quality and affordable healthcare solutions to patients worldwide. With a strong emphasis on research and development, Ajanta Pharma Ltd strives to continuously develop and introduce new, cutting-edge pharmaceutical products. Their corporate philosophy revolves around the belief in creating value for all stakeholders, including customers, employees, and shareholders. Through their dedicated efforts, Ajanta Pharma Ltd has established a reputation for providing safe and effective medications that improve the quality of people's lives globally.
Analysts currently set an average price target of 3,309.98 INR for the Ajanta Pharma stock (median: 3,304.80 INR), implying -2.1 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Ajanta Pharma stock: 18 recommend buying, 1 holding and 1 selling.
Converted at the current exchange rate, the Ajanta Pharma share trades at 30.85 EUR (3,283.90 INR).
The Ajanta Pharma share (AJANTPHARM.NS) is listed on 2 stock exchanges, including: NSE (Indien) (AJANTPHARM.NS).
Ajanta Pharma Ltd is a multinational company based in India. It specializes in producing high-quality healthcare products, primarily generic drugs that are cheaper alternatives to branded medications. One of its main focuses is producing generics for treating sexual dysfunction. The company also manufactures a wide range of innovative medications in various therapeutic areas, including dermatology, ophthalmology, neurology, nephrology, and oncology. Some of its key products include Kamagra, an effective treatment for erectile dysfunction in men; Tadalafil, also known as Cialis, for improving erectile function; and Sildenafil Citrate, marketed as "Viagra". Ajanta Pharma Ltd also produces Active Pharmaceutical Ingredients (APIs) that are distributed globally and used in various medications. It is committed to providing high-quality medicines at affordable prices and strives to improve access to healthcare for everyone. The company emphasizes innovation and invests in research and development to meet customer needs. It also maintains strategic partnerships with international healthcare companies to expand its scientific expertise. Ajanta Pharma Ltd generated over $1 billion in revenue last year and employs around 9,800 people worldwide. It operates in more than 30 countries and has six modern manufacturing facilities in India. Overall, Ajanta Pharma Ltd aims to promote sustainable development in the healthcare sector and plans to further expand its presence in the coming years.
The revenue of Ajanta Pharma is 54.53 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Ajanta Pharma is 10.56 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Ajanta Pharma is currently 38.90. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ajanta Pharma stock.
The price-to-sales ratio (P/S) of Ajanta Pharma is currently 7.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ajanta Pharma stock.
The Eulerpool Quality Score for Ajanta Pharma is 8/10.
The ISIN of Ajanta Pharma is INE031B01049. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Ajanta Pharma is AJANTPHARM.NS. The ticker symbol is used to trade Ajanta Pharma shares on the stock exchange.
Ajanta Pharma stock
Ajanta Pharma Peer Group
Ajanta Pharma Ticker
Ajanta Pharma FIGI
All fundamentals and in-depth analysis of Ajanta Pharma
Our stock analysis for Ajanta Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ajanta Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.